KR20060034231A - 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도 - Google Patents

암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도 Download PDF

Info

Publication number
KR20060034231A
KR20060034231A KR1020057023460A KR20057023460A KR20060034231A KR 20060034231 A KR20060034231 A KR 20060034231A KR 1020057023460 A KR1020057023460 A KR 1020057023460A KR 20057023460 A KR20057023460 A KR 20057023460A KR 20060034231 A KR20060034231 A KR 20060034231A
Authority
KR
South Korea
Prior art keywords
epha4
antibody
cancer
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057023460A
Other languages
English (en)
Korean (ko)
Inventor
켈리 칼레스-킨치
마이클 에스. 킨치
Original Assignee
메디뮨 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 인코포레이티드 filed Critical 메디뮨 인코포레이티드
Publication of KR20060034231A publication Critical patent/KR20060034231A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020057023460A 2003-06-06 2004-06-07 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도 Withdrawn KR20060034231A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47690903P 2003-06-06 2003-06-06
US60/476,909 2003-06-06
US50335603P 2003-09-16 2003-09-16
US60/503,356 2003-09-16

Publications (1)

Publication Number Publication Date
KR20060034231A true KR20060034231A (ko) 2006-04-21

Family

ID=34622735

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057023460A Withdrawn KR20060034231A (ko) 2003-06-06 2004-06-07 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도

Country Status (7)

Country Link
US (2) US7604799B2 (https=)
EP (1) EP1638514A4 (https=)
JP (1) JP2007522096A (https=)
KR (1) KR20060034231A (https=)
AU (1) AU2004291026A1 (https=)
CA (1) CA2528549A1 (https=)
WO (1) WO2005048917A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US9032097B2 (en) * 2001-04-26 2015-05-12 Nokia Corporation Data communication with remote network node
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1606305A4 (en) 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
KR20060034231A (ko) * 2003-06-06 2006-04-21 메디뮨 인코포레이티드 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
DK1730196T3 (da) 2004-03-12 2011-03-28 Vasgene Therapeutics Inc EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
CN101072797B (zh) 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
US20070128116A1 (en) * 2005-07-27 2007-06-07 Wang Zheng J Multifunctional core for molecular imaging and targeted delivery of macromolecules and drugs
US7807459B2 (en) * 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
AU2006331775A1 (en) * 2005-12-21 2007-07-05 Medimmune, Llc Affinity optimized EphA2 agonistic antibodies and methods of use thereof
US8003098B2 (en) 2006-02-28 2011-08-23 Oncotherapy Science, Inc. Methods for damaging cells using effector functions of anti-EphA4 antibodies
CA2696164C (en) 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
US20100256214A1 (en) * 2009-04-02 2010-10-07 Burnham Institute For Medical Research Eph receptor ligands and methods of use
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
EP2366714A1 (en) * 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
WO2012078703A2 (en) * 2010-12-08 2012-06-14 Fox Chase Cancer Center Inhibiting chromosome instability in ovarian cancer
NZ611428A (en) * 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
JP5961608B2 (ja) * 2011-04-25 2016-08-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
JP6811706B2 (ja) * 2014-07-31 2021-01-13 ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用
EA201792380A1 (ru) * 2015-04-29 2018-04-30 Сэнфорд-Бёрнхэм Медикал Рисёрч Инститьют Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен
WO2017043466A1 (ja) * 2015-09-08 2017-03-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ＥｐｈＡ４抗体
CN108108589B (zh) * 2017-12-29 2020-06-12 郑州轻工业学院 基于网络指标差异分析的食管鳞癌标记物的识别方法
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano
US20230203096A1 (en) * 2020-04-23 2023-06-29 The Regents Of The University Of California Epha4 targeting compounds and methods of use thereof
US11732007B2 (en) 2020-09-28 2023-08-22 The Regents Of The University Of California Therapeutic compounds and methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US224374A (en) * 1880-02-10 Extension-ladder
US28685A (en) * 1860-06-12 Peed-water apparatus for steam-boilers
US622711A (en) * 1899-04-11 render
US503356A (en) * 1893-08-15 Wire-netting machine
US180823A (en) * 1876-08-08 Improvement in farm-gates
US476909A (en) * 1892-06-14 Rail-cleaning attachment for cars
US952560A (en) * 1909-06-28 1910-03-22 Gewerkschaft Der Stein Kohlenzeche Mont Cenis Process of obtaining ammonium sulfate from gases.
FI85768C (fi) 1990-07-04 1992-05-25 Valtion Teknillinen Foerfarande foer utfoerning av ytplasmonresonansmaetning samt i foerfarandet anvaendbar givare.
DE69110032T2 (de) 1991-06-08 1995-12-21 Hewlett Packard Gmbh Verfahren und Gerät zur Feststellung und/oder Konzentrationsbestimmung von Biomolekülen.
GB9623820D0 (en) 1996-11-16 1997-01-08 Secr Defence Surface plasma resonance sensor
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
JP2002518663A (ja) 1998-05-20 2002-06-25 グラッフィニティ ファルマシューティカル デザイン ゲーエムベーハー 液体状態で存在する多数の試料を同時に測定するためのｓｐｒセンサー
US6289286B1 (en) 1998-05-29 2001-09-11 Biacore Ab Surface regeneration of biosensors and characterization of biomolecules associated therewith
AU5761900A (en) * 1999-06-30 2001-01-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human monoclonal antibodies to hiv-1 envelope glycoprotein gp120
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2411601A1 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US20020025536A1 (en) * 2000-06-26 2002-02-28 Jeno Gyuris Methods and reagents for isolating biologically active antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
EP1410011B1 (en) 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnosis and prognosis of breast cancer patients
ATE525398T1 (de) 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
AU2003268345A1 (en) 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
KR20060034231A (ko) * 2003-06-06 2006-04-21 메디뮨 인코포레이티드 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES

Also Published As

Publication number Publication date
WO2005048917A3 (en) 2009-03-26
EP1638514A2 (en) 2006-03-29
US20100166657A1 (en) 2010-07-01
EP1638514A4 (en) 2009-11-18
JP2007522096A (ja) 2007-08-09
US20050013819A1 (en) 2005-01-20
US7604799B2 (en) 2009-10-20
AU2004291026A1 (en) 2005-06-02
CA2528549A1 (en) 2005-06-02
WO2005048917A2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
KR20060034231A (ko) 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도
JP4557714B2 (ja) ＥｐｈＡ２モノクローナル抗体およびその使用法
JP4585968B2 (ja) ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
KR102618312B1 (ko) 항muc16 항체 및 그의 용도
JP5751680B2 (ja) アンタゴニストのヒトｌｉｇｈｔ特異的ヒトモノクローナル抗体
JP4860477B2 (ja) ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
AU2019215202A1 (en) Antibodies to Galectin-3 and methods of use thereof
US20050152899A1 (en) EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2005016381A2 (en) Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
JP2009521219A (ja) 親和性最適化ＥｐｈＡ２アゴニスト抗体およびその使用法
CN102282172B (zh) 抗伸展的ⅰ型鞘糖脂抗体、其衍生物以及用途
CN101227921A (zh) EphA4和EphA4调节剂用于诊断、治疗和预防癌症的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051206

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid